Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Healthcare Biotechnology
Oncolytics Biotech Inc. is a biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to phase 3 licensure-enabling studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Oncolytics Biotech Inc > Background to Gilead's $21 Bln acquisition of Immunomedics
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(5809)
•••
Comment by Noteableon Apr 09, 2022 5:05pm
186 Views
Post# 34591095

RE:RE:Background to Gilead's $21 Bln acquisition of Immunomedics

RE:RE:Background to Gilead's $21 Bln acquisition of Immunomedics
April 08, 2022 -    " In draft guidance, the National Institute of Health and Care Excellence has rejected Gilead Sciences’ Trodelvy for use against triple negative breast cancer (TNBC), saying it is too expensive for use by the National Health Service (NHS)."

“Given the lack of treatment options for people with this type of breast cancer, we’re very disappointed that its price means we can’t recommend it for use in the NHS at this point,” Helen Knight, interim director of medicines evaluation at NICE, said in a release."


Although sacituzumab govitecan (also called Trodelvy) increases how long people have before their disease gets worse and how long they live compared with chemotherapy, at its current price it is too expensive to be considered a cost-effective use of NHS resources.


The aim of treatment is to stop the disease getting worse, extend life, and maintain or improve quality of life for as long as possible.


[ With regards to the above referenced aim of treatment - these are the aims that ONCY's pelareorep + paclitaxel doublet combination  and the pelareorep + paclitaxel + immune checkpoint inhibitor triplet cocktail have set out to acheive in metastatic breast cancers including TNBC.]
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities